Search details
1.
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021.
Eur J Clin Microbiol Infect Dis
; 2024 May 22.
Article
in English
| MEDLINE | ID: mdl-38775873
2.
Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents - SMART 2018-2021.
J Formos Med Assoc
; 123(3): 400-407, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-37735013
3.
In Vitro Activity of Ceftibuten-Avibactam against ß-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program.
Antimicrob Agents Chemother
; 67(1): e0134622, 2023 01 24.
Article
in English
| MEDLINE | ID: mdl-36602322
4.
In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates.
Antimicrob Agents Chemother
; 67(12): e0034623, 2023 12 14.
Article
in English
| MEDLINE | ID: mdl-37971240
5.
In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program.
Antimicrob Agents Chemother
; 67(1): e0128122, 2023 01 24.
Article
in English
| MEDLINE | ID: mdl-36541767
6.
In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019).
J Antimicrob Chemother
; 78(8): 2019-2027, 2023 08 02.
Article
in English
| MEDLINE | ID: mdl-37390312
7.
Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017-2019.
J Antimicrob Chemother
; 78(7): 1606-1615, 2023 07 05.
Article
in English
| MEDLINE | ID: mdl-37161662
8.
In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021.
Eur J Clin Microbiol Infect Dis
; 42(9): 1135-1143, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37526796
9.
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland-SMART 2017-2020.
Eur J Clin Microbiol Infect Dis
; 42(3): 365-370, 2023 Mar.
Article
in English
| MEDLINE | ID: mdl-36670243
10.
In Vitro Activity of Ceftibuten/VNRX-5236 against Urinary Tract Infection Isolates of Antimicrobial-Resistant Enterobacterales.
Antimicrob Agents Chemother
; 66(1): e0130421, 2022 01 18.
Article
in English
| MEDLINE | ID: mdl-34662183
11.
In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019.
Antimicrob Agents Chemother
; 66(2): e0199021, 2022 02 15.
Article
in English
| MEDLINE | ID: mdl-34807757
12.
In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes.
Antimicrob Agents Chemother
; 66(2): e0216521, 2022 02 15.
Article
in English
| MEDLINE | ID: mdl-34930028
13.
Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-ß-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018-2020 Global Surveillance Collection.
Antimicrob Agents Chemother
; 66(11): e0093422, 2022 11 15.
Article
in English
| MEDLINE | ID: mdl-36286518
14.
In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020.
Antimicrob Agents Chemother
; 66(5): e0018922, 2022 05 17.
Article
in English
| MEDLINE | ID: mdl-35491836
15.
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
Clin Infect Dis
; 72(12): 2112-2120, 2021 06 15.
Article
in English
| MEDLINE | ID: mdl-32246147
16.
Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017.
Antimicrob Agents Chemother
; 65(7): e0200020, 2021 06 17.
Article
in English
| MEDLINE | ID: mdl-33972241
17.
Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019.
BMC Microbiol
; 21(1): 74, 2021 03 06.
Article
in English
| MEDLINE | ID: mdl-33676406
18.
In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems.
Antimicrob Agents Chemother
; 64(12)2020 11 17.
Article
in English
| MEDLINE | ID: mdl-32928739
19.
Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17.
J Antimicrob Chemother
; 75(5): 1165-1173, 2020 05 01.
Article
in English
| MEDLINE | ID: mdl-32040168
20.
In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.
Antimicrob Agents Chemother
; 63(4)2019 04.
Article
in English
| MEDLINE | ID: mdl-30670424